ClinicalTrials.gg
Status unknownNCT03529487Updated Aug 2, 2022

Intra-anal Oxymetazoline in Healthy Adult Volunteers

A Phase 1 interventional study of Oxymetazoline in Fecal Incontinence, sponsored by RDD Pharma Ltd. Status unknown at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-02.

Sponsored by RDD Pharma Ltd · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies in Fecal Incontinence with a site in United States — 14 open to participants now, 19 under way, 2 of them phase 3. Fecal Incontinence · United States.

Planned enrollment
42nd of 79
40 · median 44
Started
2018
with 5 others
Phase 1
5 of 101
none open now
Registered
61st of 101
by date

Among the 101 studies in Fecal Incontinence with a site in United States, this one is the 42nd largest by planned enrollment of the 79 interventional ones that give a count, is one of 6 that started in 2018, is one of 5 in phase 1, and was the 61st registered.

Fecal Incontinence

283 studies on the registry are indexed under Fecal Incontinence; 52 are open to participants now.

Browse Fecal Incontinence studies →

Open to participants now

14 of the 101 studies in Fecal Incontinence with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Fecal Incontinence studies recruiting now, 25 (66%) set no upper age limit and 9 (24%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Fecal Incontinence with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, open-label, repeat dose, ascending dose study assessing the PK, safety, tolerability, PD, and dose- or exposure-response of Topical Oxymetazoline for intra-anal application. A total of 32 healthy male and female subjects will be enrolled to receive either Topical Oxymetazoline 1 mg (Cohort A, n=16), 5 mg (Cohort B, n=8) and 10 mg (Cohort C, n=8) applied intra-anally daily (QD) for 11 consecutive days.

Read the detailed description

This is a Phase 1, open-label, repeat dose, ascending dose study assessing the PK, safety, tolerability, PD, and dose- or exposure-response of Topical Oxymetazoline for intra-anal application.

The primary objective of this study is to determine the plasma concentrations and PK parameters, as data allows, of oxymetazoline following single and repeated intra-anal application of oxymetazoline gel 1 mg, 5 mg or 10 mg in healthy male and female subjects.

The secondary objective of this study is to evaluate the safety and tolerability of repeated intra-anal application of oxymetazoline gel 1 mg, 5 mg or 10 mg in healthy male and female subjects.

A total of 32 healthy male and female subjects will be enrolled (16 subjects in the first cohort and 8 subjects in the remaining cohorts) and will be exposed to Topical Oxymetazoline 1 mg, 5 mg or 10 mg applied intra-anally QD for 11 consecutive days.

03

Conditions studied

  • Fecal Incontinence

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. An Institutional Review Board (IRB) approved is signed and dated prior to any study-related activities.
  2. Subject is an adult male or female between the ages of 18 and 60 years, inclusive.
  3. Female subjects of must have a negative urine pregnancy test. Females of childbearing potential must practice a highly effective method of pregnancy prevention (defined as \<1% pregnancies per 100 women per year) from one month before screening to one month after the follow-up visit, such as: surgical sterilization, hormonal implant, intrauterine device, or male condom + female diaphragm + vaginal spermicide. Female subject with any of the following circumstances is not required to use a highly effective method of pregnancy prevention: status post-hysterectomy; or, status post-tubal ligation; or, state (defined as >= 12 months of spontaneous amenorrhea) or \< 12 months of spontaneous amenorrhea with a blood follicle stimulating hormone > 40 MIU/ml.
  4. Subject has a between 18 and 33 kg/m2 (weight/[height]2).
  5. Subject has normal (or abnormal and clinically insignificant) laboratory values at Screening.
  6. Subject is healthy based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring and have no more than 3 spontaneous bowel movements (SBM) a day or no less than 3 SBMs a week.
  7. Based on single or averaged values of triplicate ECGs over a brief recording period, QTc \< 450 msec
  8. Subject has the ability to understand the requirements of the study and a willingness to comply with all study procedures, including retaining a rectal gel for at least 60 min and undergoing repeat rectal manometries lasting 10-15 min.
  9. Subject has not consumed and agrees to abstain from taking any prescription or non-prescription medications, including herbal and dietary supplements (such as St. John's wort) within 14 days prior to the first dose of study medication (except as authorized by the Investigator and Medical Monitor).
  10. Subject has not consumed alcohol-containing beverages for 3 days prior to the first scheduled dose and agrees not to consume alcohol through the last study visit.
  11. Subject has not used tobacco- and nicotine-containing products for 2 months prior to the first scheduled dose and agrees not to use through the last study visit.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a or allergy to oxymetazoline.
  2. Subject has active or history of cardiovascular or cerebrovascular disease including hypertension, unstable angina, myocardial infarction, /stroke, arrhythmia, congestive heart failure, or cardiac valve abnormalities.
  3. Subject has systolic blood pressure >130 mm Hg and/or diastolic blood pressure >80 mm Hg and/or resting heart rate >90 bpm or resting heart rate \<50 bpm.
  4. Subject has glaucoma (narrow-angle), Raynaud's disease/phenomenon, thromboangiitis obliterans, scleroderma, and/or Sjögren's syndrome.
  5. Subject has diabetes per medical history or has fasting plasma glucose level > 7 mmol/l (126 mg/dl) at screening or has (HbA1C) ≥ 48 mmol/mol (≥ 6.5 DCCT %) at screening.
  6. Subject has thyroid problems such as medical history of hypothyroidism, hyperthyroidism, sick euthyroid syndrome, thyroid cancer, thyroid surgery, Radioiodine treatment or enlarged thyroid upon physical examination, or thyroid nodule upon physical examination, or abnormal thyroid-stimulating hormone (TSH) at screening defined as level >4.0 mIU/mL or level \<0.4 mIU/mL.
  7. Subject with enlarged prostate as per medical history or per rectal examination in screening.
  8. Subject has a history of rectal surgery.
  9. Subject has upon physical examination a rectal deformation or signs of rectal disease such as fissure, hemorrhoids grade 3, rectal prolapse, fistula, infection or space occupying lesion.
  10. Subjects with a history of or present symptoms related to irritable bowel disease, inflammatory bowel disease, or chronic constipation.
  11. Subject reporting change in bowel habits in the last 14 days.
  12. Subject reporting episodes of rectal bleeding in the last 90 days.
  13. Subjects taking anticoagulants such as Coumarins, Heparins, and Factor Xa inhibitors.
  14. Subjects taking drugs known to affect rectal tone: nitrates, calcium channel blockers, alpha antagonists, and alpha agonists.
  15. Subjects taking beta-blockers, and/or cardiac glycosides.
  16. Subjects taking anti-hypertensives such as diuretics, beta blockers, alpha antagonists, sympatholytics, ACE inhibitors, angiotensin II antagonists, renin inhibitors, calcium antagonists or direct vasodilators.
  17. Subjects taking anti-diabetic medications such as insulin, Biguanides, α-Glucosidase Inhibitors, Dipeptidyl peptidase IV inhibitors, Insulin secretagogues, Sodium-glucose cotransporter 2 inhibitors, Thiazolidinediones, Amylin agonists, GLP-1 receptor-agonists.
  18. Subjects taking drugs affecting the thyroid such as levothyroxine, propylthiouracil, methimazole or amiodarone.
  19. Subject has a history illicit drug abuse in the past year or current evidence of such abuse in the opinion of the Investigator.
  20. Subject has positive findings on urine drug/alcohol/cotinine screen.
  21. Subject is positive for (HIV), and/or on Screening assessments.
  22. Subject has an abnormal screening lab results judged by the investigator as clinically significant.
  23. Subject has thrombocytopenia defined as level \< 150,000 per microliter of blood.
  24. Subject is pregnant or lactating.
  25. Subject has an acute illness within 1 week of the first scheduled dose.
  26. Subject has donated plasma within 7 days of drug administration.
  27. Subject has donated 1 or more pints of blood (or equivalent blood loss) within 30 days prior to drug administration.
  28. Subject has participated in an drug study where the last assessment of that study was within the 30 days prior to the first scheduled dose of this study.
  29. Subject is an immediate family member of personnel directly affiliated with the study, or is personally directly affiliated with the study at the investigative site, or is employed or related to the Sponsor, CRO or investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Oxymetazoline applied intra analy

    Drug: Oxymetazoline

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Oxymetazoline Maximum observed plasma concentration

    Time frame: 11 days

  2. Tmax

    Time to maximum concentration (Oxymetazoline), obtained directly from the observed concentration versus time data

    Time frame: 11 days

  3. AUClast

    Oxymetazoline Area under the plasma concentration-time curve from time 0 to time of last measureable plasma concentration

    Time frame: 11 days

  4. t½

    Oxymetazoline Terminal elimination half-life

    Time frame: 11 days

07

Study locations

1 site
  • Spaulding Clinical Research, LLC
    West Bend, Wisconsin 53095, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2018 (actual). Primary completion is estimated for Dec 2023, 63 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2018
First posted
May 18, 2018
StartActual
Aug 20, 2018
Primary completionEst.
Dec 1, 2023
CompletionEst.
Dec 1, 2023
Last update
Aug 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03529487
Lead sponsor
RDD Pharma Ltd
Collaborators
United States Department of Defense, Spaulding Clinical Research LLC
Responsible party
Sponsor
First posted
May 18, 2018
Start date
Aug 20, 2018
Primary completion
Dec 1, 2023 (estimated)
Completion
Dec 1, 2023 (estimated)
Last update
Aug 2, 2022

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxymetazoline

Start the discussion